tirzepatide weight loss surmount-1 results percent weight loss 72 weeks trial percentage Tirzepatide cuts diabetes risk by 94% in SURMOUNT-3: Tirzepatide shows total mean

Zepbound is approved for chronic weight management and obstructive sleep apnea

Poor adherence and persistence to sodium glucose co-transporter 2 inhibitors in real-world settings: evidence from a systematic review and meta-analysis

What are GLP-2s

GLP-1 secretion may be normal or modestly reduced in type 2 diabetes, with considerable variability across studies

Serious adverse effects , though rare, can include pancreatitis, gallbladder problems, and kidney complications

To clarify why the GLP-1R ends up in the lysosome, we investigated whether inhibition of protein degradation could restore GLP-1R expression (Fig